IDH3A and acute myeloid leukemia: Given the essential role of mitochondrial dependence in AML, the U.S. Food and Drug Administration (FDA) has approved several therapies for AML treatment, including the isocitrate dehydrogenase one inhibitor ivosidenib (6), the isocitrate dehydrogenase two inhibitor enasidenib (8), and the BH3 mimetic venetoclax (18).